NHS launches STRIDE trial: can GP blood tests spot abdominal cancers earlier?
- More than 20,000 patients at at least 200 GP practices in England will take part in a trial of cancer-detecting blood tests.
- The STRIDE-RCT trial targets people aged 45 and over who see their GP with abdominal symptoms such as persistent bloating.
- The tests, largely developed at the University of Birmingham, look for signs of several cancers in one sample.
- A positive result will not be a diagnosis; it will help GPs decide who needs urgent referral.
A major trial launched on 4 November 2026 will test whether simple blood tests taken at the GP surgery can help find abdominal cancers earlier. The STRIDE-RCT trial will enrol more than 20,000 NHS patients at at least 200 GP practices across England, the Department of Health and Social Care announced.
Who can take part
Patients aged 45 and over who visit their GP with abdominal symptoms, such as persistent bloating or discomfort, will be offered the chance to join. Most tests require one or two extra tubes of blood taken alongside routine tests. They look for signs of several cancers in a single sample, including prostate, ovarian, bowel, pancreatic, stomach and liver cancer, and try to suggest where in the body a cancer comes from, using methods such as protein measurement and artificial intelligence.
Why it matters
About 71,000 people in England are diagnosed with pancreatic, stomach, liver, ovarian or bowel cancer each year, with almost 35,000 deaths. Around 9 in 10 people with stage 1 bowel cancer survive five years, compared with about 1 in 10 at stage 4. At present only 2% to 6% of urgent cancer referrals lead to a diagnosis, so a better triage tool could free appointments for those most at risk.
Limits
A positive result is not a cancer diagnosis; it will help the GP decide whether urgent referral is needed. Co-chief investigator Professor Aneel Bhangu said the tests "might" help GPs separate patients with and without cancer, but that certainty is needed before NHS-wide use. The trial is funded with up to £8.49 million through the National Institute for Health and Care Research.
Source: Department of Health and Social Care (GOV.UK)
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is the STRIDE cancer blood test trial?
STRIDE-RCT is an NHS trial in England testing whether GP blood tests can help detect abdominal cancers earlier in more than 20,000 patients with abdominal symptoms.
Who is eligible for the STRIDE trial?
Patients aged 45 and over who see their GP in a participating practice with abdominal symptoms such as persistent bloating or discomfort may be offered a place.
Which cancers do the STRIDE blood tests look for?
The STRIDE blood tests look for signs of cancers including prostate, ovarian, bowel, pancreatic, stomach and liver cancer.
Does a positive blood test mean a person has cancer?
No. In the STRIDE trial a positive blood test is not a diagnosis; it helps the GP decide whether the patient needs an urgent referral for further tests.
Why is early detection of bowel cancer important?
Around 9 in 10 people diagnosed with stage 1 bowel cancer survive at least five years, compared with about 1 in 10 diagnosed at stage 4.


